Kruti Joshi, MPH

  • 4Articles
  • 114.9KReads
  • 2021–2025Active
  • 20Collaborators
  • 954Citations

About

Kruti Joshi, MPH, is affiliated with Janssen Scientific Affairs, LLC, a Johnson & Johnson company in Titusville, New Jersey. Joshi has published research from 2021 to 2025 focusing on major depressive disorder (MDD) and suicide, including studies on treatment-resistant depression, economic burden, and barriers to esketamine nasal spray treatment. The author has contributed to analyses of work productivity loss, national prevalence, and costs associated with depression and suicidal ideation. Collaborations frequently include Dominic Pilon, Maryia Zhdanava, John J. Sheehan, Patrick Lefebvre, and Aditi Shah.

Publications

JCP
Esketamine Nasal Spray vs Quetiapine ER in Treatment-Resistant Depression
Original Research

Esketamine Nasal Spray vs Quetiapine ER in Treatment-Resistant Depression

January 27, 2025

Esketamine was associated with significantly larger improvements in work productivity loss and related costs compared to quetiapine, suggesting greater benefits from patient well-being and employer perspectives.
, , , et al
JCP
Barriers to Esketamine Nasal Spray Use in Treatment-Resistant Depression
Original Research

Barriers to Esketamine Nasal Spray Use in Treatment-Resistant Depression

May 6, 2024

Potential barriers to treatment with esketamine nasal spray include travel distance, insurance, low socioeconomic status, and minority communities.
, , , et al
JCP
Economic Burden of MDD and Suicidality
Original Research

Economic Burden of MDD and Suicidality

April 4, 2022

Acute suicidal ideation or behavior (SIB) that accompanies major depressive disorder (MDD) may produce a substantial economic burden. This study evaluated health care resource utilization and costs of commercially...
, , , et al
JCP
Original Research

Prevalence and Burden of TRD and MDD

March 16, 2021

How prevalent is treatment-resistant depression (TRD), and what proportion of the burden of medication-treated major depressive disorder is accounted for by TRD? This study explores those questions using the...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe